Hence, based on this mechanism, the interference of KNG1–BDKRB1(a receptor for KNG1) and/or IL6-IL6R (a receptor for IL6) interactions could bring a therapeutic benefit to IPF. This evidence concerns the gene BDKRB1 and idiopathic interstitial pneumonia.